LUYE PHARMA (02186): Innovative Drug LY03021 Approved to Conduct Clinical Trial in the United States
LUYE PHARMA (02186) announced that LY03021, a next-generation central nervous system (CNS) investigational new drug independently developed by the Group, has received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials, and is intended for the treatment of depression. To the best of the Group's knowledge, LY03021 is the world's first gamma-aminobutyric acid type A receptor (GABAAR) positive allosteric modulator, dopamine transporter (DAT) and norepinephrine transporter (NET) inhibitor.
LUYE PHARMA (02186) announces that LY03021, a next-generation central nervous system (CNS) investigational new drug independently developed by the group, has received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials, with the intended indication of depression. To the group's knowledge, LY03021 is the world's first gamma-aminobutyric acid type A receptor (GABAAR) positive allosteric modulator, dopamine transporter (DAT) and norepinephrine transporter (NET) inhibitor.
Depression affects a broad population and imposes a heavy disease burden. Data show that approximately 322 million people worldwide suffer from the disease; in 2025, approximately 20 million adults in the United States experienced a major depressive episode in the past year. Depression is often comorbid with psychiatric disorders such as anxiety disorders and may be accompanied by more severe functional impairment.
Existing antidepressant drugs generally have an onset of action of 24 weeks, and a considerable proportion of patients have difficulty achieving full remission; after treatment, patients may still have residual symptoms such as anxiety, lack of energy or anhedonia, and drug-related adverse reactions such as sexual dysfunction may also affect treatment compliance. In addition, although a small number of fast-acting antidepressants have been approved for marketing, their clinical application has significant limitations: restricted applicable settings (requiring in-hospital supervised administration), and associated with higher risks of sedation, dissociative reactions, loss of consciousness and abuse. Therefore, how to rapidly and effectively control the clinical symptoms of depression, further improve treatment outcomes and prognosis, while also taking into account ease of use and safety, has become an unresolved challenge in current antidepressant drug development.
LY03021 was developed based on the group's AI innovative drug platform TransNEXCEEDTM and is a first-in-class three-target antidepressant innovative drug that acts simultaneously on GABAAR, DAT and NET. On the one hand, LY03021 selectively targets the synaptic 122 subtype and extrasynaptic 43 subtype of GABAAR, and rapidly exerts antidepressant and anxiolytic effects by regulating the glutamate-GABAergic balance in the brain. Its high selectivity for extrasynaptic GABAAR subtypes reduces the risks of sedation, somnolence, loss of consciousness and reduced long-term efficacy caused by excessive activation of synaptic subtypes. On the other hand, LY03021 increases brain levels of dopamine (DA) and norepinephrine (NE) by inhibiting DAT and NET, regulating reward and mood pathways, which not only effectively relieves core symptoms of depression such as low mood and diminished interest, but also specifically improves anhedonia commonly seen in depression patients as well as drug-related or disease-associated sexual dysfunction. At the same time, the arousal-promoting effects mediated by DA and NE can antagonize central inhibitory signals, mechanistically reducing the central inhibitory effects caused by excessive GABAAR activation, further optimizing central safety while achieving antidepressant efficacy.
Non-clinical studies show that 4 hours after administration, LY03021 significantly improved depression- and anxiety-like behaviors in model animals, and the efficacy remained stable when administered continuously until the end of the 56-day study; when administered once weekly, the efficacy persisted until day 7 after dosing, suggesting that LY03021 has both rapid onset and durable efficacy, supporting development of a once-weekly dosing regimen. Meanwhile, LY03021 has good safety, with its NOAEL (no observed adverse effect level) being more than 50 times the effective dose; animal studies showed no withdrawal symptoms related to physical dependence.
LY03021 is another innovative CNS drug developed by the group simultaneously in China and the United States, and a Phase I clinical study is currently being conducted in China. At present, single doses of 5 mg to 180 mg LY03021 have shown good safety and tolerability, with no adverse events of sedation, confusion or loss of consciousness observed, preliminarily validating the theory of unbalanced regulation of intra- and extrasynaptic GABAAR subtypes and three-target synergy. Non-clinical studies have suggested that the investigational drug can rapidly and continuously improve depression- and anxiety-like behaviors in animal models, and it is expected that clinically it may achieve onset of action within 12 hours of dosing and once-weekly administration, combining rapid symptom control, durable action and dosing convenience, while relying on its unique mechanism of action to avoid the sedation risk of traditional regimens, providing a new solution for the treatment of CNS diseases. The group plans to initiate Phase II clinical trials of LY03021 in China in 2027 to explore the rapid antidepressant efficacy and safety of the once-weekly dosing regimen at different doses.
The group has long been deeply engaged in the CNS therapeutic field, and multiple products have been successfully launched in markets including China, the United States, Europe and Japan, while it continues to advance global development of next-generation innovative drugs. In addition to LY03021, the group has several other new molecular entities with differentiated features in clinical stages. Among them, LY03015 is the world's only VMAT2/Sigma-1R dual-target innovative drug, intended for the treatment of tardive dyskinesia and Huntington's disease-associated chorea, and has completed Phase II clinical trials in China and a U.S. bridging study, respectively; LY03017 is a next-generation serotonin 2A receptor (5-HT2AR) inverse agonist/serotonin 2C receptor (5-HT2CR) antagonist, intended for the treatment of Alzheimer's disease psychosis, Parkinson's disease psychosis, etc.; LY03020 is the world's first trace amine-associated receptor 1 (TAAR1)/serotonin 2C receptor (5-HT2CR) dual-target agonist, intended for the treatment of schizophrenia, Alzheimer's disease psychosis, etc. Both LY03017 and LY03020 are in Phase II clinical stages in China and have been approved to conduct clinical trials in the United States.
Related Articles

BOAN BIOTECH (06955): BA1104 (nivolumab) China Phase III clinical trial completed and met primary endpoint

CR CONSTRUCTION (01582) Clarification: CR Sea and the petitioner have not entered into any settlement agreement, and neither CR Sea nor the subcontractor has taken any steps to initiate proceedings to withdraw the petition.

HK Stock Market Move | PEIPORT HOLD (02885) surged over 24% to a new high as Hong Kong Lap completed the acquisition of 70% of its share capital and made an offer.
BOAN BIOTECH (06955): BA1104 (nivolumab) China Phase III clinical trial completed and met primary endpoint

CR CONSTRUCTION (01582) Clarification: CR Sea and the petitioner have not entered into any settlement agreement, and neither CR Sea nor the subcontractor has taken any steps to initiate proceedings to withdraw the petition.

HK Stock Market Move | PEIPORT HOLD (02885) surged over 24% to a new high as Hong Kong Lap completed the acquisition of 70% of its share capital and made an offer.






